Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
2007

Dual Antiplatelet Therapy and Drug Eluting Stents

Sample size: 878 publication 10 minutes Evidence: moderate

Author Information

Author(s): Benezet-Mazuecos Juan, Ibanez Borja, Badimon Juan J

Primary Institution: Mount Sinai School of Medicine

Hypothesis

Does the use of drug-eluting stents (DES) increase the risk of late in-stent thrombosis compared to bare metal stents (BMS)?

Conclusion

The study suggests that while drug-eluting stents reduce restenosis, they may increase the risk of late in-stent thrombosis compared to bare metal stents.

Supporting Evidence

  • Drug-eluting stents have a lower rate of restenosis compared to bare metal stents.
  • Late in-stent thrombosis rates are higher in drug-eluting stents than in bare metal stents.
  • Discontinuation of dual antiplatelet therapy is a significant risk factor for stent thrombosis.

Takeaway

This study looks at how certain heart stents can help keep arteries open but might also cause dangerous blood clots later on.

Methodology

The study involved a meta-analysis comparing outcomes of patients with drug-eluting stents and bare metal stents.

Potential Biases

Potential biases may arise from the retrospective nature of some studies included in the meta-analysis.

Limitations

The study primarily focuses on first-generation drug-eluting stents and may not reflect outcomes with newer stent technologies.

Participant Demographics

Patients undergoing percutaneous coronary interventions, including those with diabetes and advanced age.

Statistical Information

P-Value

0.01

Statistical Significance

p=0.01

Digital Object Identifier (DOI)

10.1186/1477-9560-5-15

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication